Nelson Whistance Named VP of U.S. Sales At Gynesonics

IN.PACT AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions

The data, which were presented virtually as a podium first at the 2021 Charing Cross Symposium, demonstrated that the IN.PACT™ AV drug-coated balloon (DCB) is the first and only DCB to show sustained and superior effectiveness through two years compared to standard percutaneous transluminal angioplasty (PTA) in end-stage renal disease (ESRD) patients with de novo or non-stented restenotic native arteriovenous fistulae (AVF) in the upper extremity.

Martell Diagnostic Laboratories Announces HERTEST: Groundbreaking Way to Detect Effectiveness of Breast Cancer RX Globally

HERTEST is a blood test that looks for a protein called human epidermal growth factor receptor (HER2), which is shed into the blood stream of patients with growing breast cancer tumors.

ESPRIT CAM Improves Productivity for Long Part Machining by Automating Multi-spindle Program Creation

ESPRIT CAM: New computer-aided-manufacturing (CAM) technology has been introduced by ESPRIT CAM, part of Hexagon’s Manufacturing Intelligence division that provides manufacturers with the control and flexibility needed to use multi-spindle and multi-channel computer-numerical-control (CNC) machinery for the machining of long parts.

Nelson Whistance has been named Vice President of U.S. sales of Gynesonics. The news was announced today.

“Nelson Whistance is a proven sales leader that has spent the majority of his medical device career driving commercial business in minimally invasive gynecologic surgery. He brings a strong combination of business acumen, process-oriented leadership, has exceptional clinical expertise and a track record of developing world-class training programs for physicians and commercial teams, that will enable us to scale rapidly. Nelson will support our mission of creating an impactful and lasting improvement in the standard of care for women who suffer from symptomatic uterine fibroids,” Owens said. “As we are on the precipice of the full commercial launch of our Sonata® 2 next-generation system, Nelson adds these critical elements to the executive leadership team along with his proven success in driving disruptive technology adoption in the U.S. and Canada.”

Nelson Whistance said, “I’m thrilled to be joining Gynesonics at such a critical inflection point, as we are rapidly expanding access to this groundbreaking technology in the U.S. and globally. The Sonata procedure is going to revolutionize the care of women with symptomatic uterine fibroids, and I’m honored to have been selected to build a world-class sales organization that will live up to its promise.”

Prior to joining Gynesonics, Mr. Whistance has successfully grown businesses and led commercial teams for various healthcare companies in the United States and Canada. He has led sales teams in multiple product launches, partnered with physician leaders to drive site-of-care optimization and built top quality sales training and development programs.

Previously, Mr. Whistance was Vice President of Sales and Marketing for Prytime Medical Devices, supporting the commercial market adoption of the ER-REBOA™ Catheter portfolio. Prior to Prytime, Mr. Whistance held various positions in sales, sales field training and sales management for the surgical division of Hologic supporting the MyoSure® and NovaSure® gynecological technologies. Mr. Whistance has held various sales and leadership roles for American Medical Systems, Servier Canada Pharmaceuticals, and Sysco Edmonton.

Mr. Whistance is a graduate of the University of Alberta, with a bachelor’s degree in Secondary Education.

 

spot_img

DON'T MISS

Related Articles